CDCP1, a transmembrane protein with tumor pro-metastatic activity, was recently identified as a prognostic marker in TNBC, the most aggressive breast cancer subtype still lacking an effective molecular targeted therapy. | The PDGFRβ ERK1 2 pathway regulates CDCP1 expression in triple-negative breast cancer